Abstract 145P
Background
IO ± chemotherapy (CT) is first-line therapy for mNSCLC without actionable mutations. We aimed to identify a genomic signature potentially predicting resistance to IO using NGS.
Methods
Pts with mNSCLC who received IO or CT/IO were eligible. NGS was performed by TSO500HT® assay (DNA [522 genes], RNA [55 genes], Tumor Mutational Burden, Microsatellite Instability) or Oncomine Focus Assay® (DNA, 35 genes) plus Archer’s FusionPlex Lung Panel® (RNA, 17 genes), according to quality/quantity cellularity. A least absolute shrinkage and selection operator (LASSO) Cox regression was conducted to choose genes. The correlation between LASSO-selected genes and progression-free survival (PFS) was evaluated by univariable Cox regression. A risk score was derived using regression coefficients of significant genes in the multivariable analysis. Pts were divided into two groups based on the median risk score (0 vs >0). The risk score was evaluated in a multivariable model including clinical features.
Results
56 pts were retrospectively included. 32 (57%) received CT/IO and 23 (43%) IO. Median follow-up was 10.4 months. Among 346 genes, 15 resulted potentially predictive of PFS. At univariable analysis, 6 genes were significantly correlated to PFS: AKT3 (HR 40.39, 95% IC 5.58-292.30, p<0.001), ARID5B (HR 4.98, 95% IC 1.11-22.24, p=0.04), CD276 (HR 14.33, 95% IC 2.60-78.99, p=0.002), PAX8 (HR 8.33, 95% IC 1.78-38.95, p=0.007), PDGFRB (HR 4.88, 95% IC 1.42-16.75, p=0.01) and RICTOR (HR 3.82, 95% IC 1.08-13.57, p=0.04). In the multivariable analysis PAX8 was excluded and a genomic signature with 5 genes was considered. PFS was significantly different in the two risk groups: HR 13.56, 95% IC 5.30-34.67, p<0.001, with a median PFS of 1.64 (95% IC 0.76-NA) vs 13.25 months. (95% IC 10.88-NA). The genomic signature remained prognostic in a multivariable model including age, smoke, histology and regimen (HR 15.71; 95% IC 5.19-47.52, p<0.001).
Conclusions
A genomic signature including AKT3, ARID5B, CD276, PDGFRB and RICTOR alterations was significantly associated with shorter PFS in pts receiving IO. Validation in external cohort is ongoing.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Medical Oncology Unit, Fondazione Policlinico Agosto Gemelli.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
158P - Enhancing the communication of genomic results: Understanding patient and clinician perspectives
Presenter: Eleanor Johnston
Session: Cocktail & Poster Display session
Resources:
Abstract
159P - Precision medicine-based platform to guide the treatment of EML4-ALK fusion lung cancers and other NSCLC
Presenter: Nathan Merrill
Session: Cocktail & Poster Display session
Resources:
Abstract
160P - CICLADES-CE study: Genomic signatures detected in DNA from FFPE samples of patients with advanced or metastatic breast cancers treated with anti-aromatase and CDK4/6 inhibitors
Presenter: Margaux BETZ
Session: Cocktail & Poster Display session
Resources:
Abstract
161P - PDL1 expression and its relation to EML4-ALK gene variants in metastatic lung adenocarcinoma: A single-center real-world experience
Presenter: Santhosh Meedimale
Session: Cocktail & Poster Display session
Resources:
Abstract
163P - Impact of genomic sequencing data on treatment decisions in advanced breast cancer (ABC)
Presenter: Sviatoslav Chekhun
Session: Cocktail & Poster Display session
Resources:
Abstract
164P - Clinical utility of comprehensive molecular profiling tests for advanced gastrointestinal tumors
Presenter: Alexandra Lebedeva
Session: Cocktail & Poster Display session
Resources:
Abstract
165P - Evaluation of the mutational profile in patients with metastatic non-small cell lung carcinoma diagnosed in a tertiary hospital which was performed by NGS method
Presenter: Kankan Deka
Session: Cocktail & Poster Display session
Resources:
Abstract
166P - Targeted next-generation sequencing as reliable detection of genetic profile for cancer treatment to guide oncologists in Pakistan
Presenter: Zeeshan Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
167P - Molecular analysis of gastrointestinal stromal tumor (GIST): The experience of Regina Elena National Cancer Institute
Presenter: Andrea Torchia
Session: Cocktail & Poster Display session
Resources:
Abstract
168P - Usefulness of liquid biopsy in the management of patients with advanced or metastatic pancreatic cancer
Presenter: Jorge Iranzo Barreira
Session: Cocktail & Poster Display session
Resources:
Abstract